Dana-Farber Cancer Institute
44 Binney Street
Boston
Massachusetts
02115
United States
Tel: 617-632-3000
308 articles about Dana-Farber Cancer Institute
-
Joseph Eid, head of medical at BMS, said Empliciti in combination with pomalidomide and dexamethasone has provided proof that the medication can extend the time a patient can live without the worsening of his or her disease.
-
Kazia Enters Clinical Collaboration to Investigate Use of Brain Cancer Drug GDC-0084 in Breast Cancer
10/22/2018
Kazia Therapeutics announced today that it will collaborate with world-leading treatment and research centre Dana-Farber Cancer Institute to investigate the use of Kazia's potential new therapy for brain cancer, GDC-0084, in breast cancer that has spread to the brain.
-
Praim Group Designs Chocolate Bars For Dana-Farber Cancer Institute
10/16/2018
Each Chocolate Bar Purchased in the Dana-Farber Holiday Cards & Gifts Collection Helps Support Pediatric and Adult Cancer Care and Research
-
BioSpace Movers and Shakers for Oct. 15
10/15/2018
Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies. -
BioSpace Movers and Shakers Sept. 24
9/24/2018
Here's a look at who's making moves in the biotech and pharma world this week. -
Merus Announces Formation of a Scientific Advisory Board
8/22/2018
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the formation of a Scientific Advisory Board (SAB), consisting of several world-renowned immuno-oncology and drug development professionals.
-
August 3 Research Roundup: Cannabidiol and Pancreatic Cancer, Metformin, Thalidomide and More
8/3/2018
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
Lilly Announces Extension of Cancer Research Collaboration with Dana-Farber Cancer Institute
7/30/2018
Extension of research collaboration focused on enhancing and speeding the process of bringing new and advanced treatments to cancer patients
-
BrainStorm Announces Second U.S. Manufacturing Site for NurOwn® Production
7/2/2018
NurOwn® is the company's ongoing randomized, double-blind, multi-dose Phase 3 clinical trial in patients with amyotrophic lateral sclerosis
-
Genetic Sequencing of Advanced Pancreatic Cancer Enables Personalized Medicine
6/14/2018
Lustgarten-Funded Research Impacting Patients in Real Time
-
Philips and Dana-Farber operationalize and scale Clinical Pathways at ASCO 2018
5/31/2018
Royal Philips announced it will be implementing Clinical Pathways from the Dana-Farber Cancer Institute
-
Foghorn Therapeutics has officially launched with a $50 million investment and the ambitious goal of altering the way our genes work.
-
Guardant Health Release: New Research Reveals Molecular Heterogeneity of Metastatic Gastroesophageal Cancer
11/16/2017
The study suggests that patients with these cancers could benefit from targeted therapy based on the detection of biomarkers found with a comprehensive liquid biopsy, but that were absent from their primary tumor.
-
Pan-Mass Challenge Announces Record-Shattering $51M Gift to Dana-Farber Cancer Institute
11/13/2017
With this gift, the PMC has brought its fundraising total to$598M since its inception in 1980.
-
The Parker Institute for Cancer Immunotherapy today announced that researchers at Dana-Farber Cancer Institute have joined its network.
-
Dana-Farber Cancer Institute Release: PCF-Funded ICECaP Study Identifies Earlier Clinical Trial Endpoint That Can Be Used To Indicate Effectiveness Of New Treatments
8/14/2017
-
Dana-Farber Cancer Institute Release: PCF-Funded ICECaP Study Identifies Earlier Clinical Trial Endpoint That Can Be Used To Indicate Effectiveness Of New Treatments
8/11/2017
-
Initial Results From Dana-Farber Cancer Institute Personalized Neoantigen Vaccine Published In Nature
7/6/2017
-
Atreca And Dana-Farber Cancer Institute Establish Broad Cancer Immunotherapy R&D Collaboration
5/31/2017
-
Actinium Announces Appointment Of Hematology Expert Dr. Richard Stone Of The Dana-Farber Cancer Institute To Its Scientific Advisory Board
5/17/2017